PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …
Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and …
Importance Approval by the US Food and Drug Administration of immune checkpoint
inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status …
inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status …
[HTML][HTML] PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee
The recent development of immune checkpoint inhibitors (ICIs) has led to promising
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …
[HTML][HTML] Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J Adam, N Le Stang, I Rouquette, A Cazes, C Badoual… - Annals of …, 2018 - Elsevier
Background Various programed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays
have been developed and used in clinical trials in association with different drugs. In order …
have been developed and used in clinical trials in association with different drugs. In order …
PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects
Immune evasion is a key strategy adopted by tumor cells to escape the immune system
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …
Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence
S Kalra, HR Tizhoosh, S Shah, C Choi… - NPJ digital …, 2020 - nature.com
The emergence of digital pathology has opened new horizons for histopathology. Artificial
intelligence (AI) algorithms are able to operate on digitized slides to assist pathologists with …
intelligence (AI) algorithms are able to operate on digitized slides to assist pathologists with …
Precision immunoprofiling by image analysis and artificial intelligence
Clinical success of immunotherapy is driving the need for new prognostic and predictive
assays to inform patient selection and stratification. This requirement can be met by a …
assays to inform patient selection and stratification. This requirement can be met by a …
[HTML][HTML] Comparison of four PD-L1 immunohistochemical assays in lung cancer
Introduction Four different programmed death ligand 1 immunohistochemical assays are
approved or in development as companion or complementary diagnostics to different …
approved or in development as companion or complementary diagnostics to different …
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: the global, multicenter EXPRESS …
M Dietel, N Savelov, R Salanova, P Micke, G Bigras… - Lung Cancer, 2019 - Elsevier
Objectives: Tumor programmed death ligand 1 (PD-L1) expression is associated with
improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted …
improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted …